PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse

Thura and colleagues report that PRL3 promotes PGCCs, which are found to be enriched in relapsed tumours. The authors demonstrated that this relapse can be prevented using PRL3-zumab for use in adjuvant immunotherapy to target PRL3-expressing PGCCs, thus preventing metastasis and relapse.

Saved in:
Bibliographic Details
Published in:Communications biology 2021-07, Vol.4 (1), p.923-923
Main Authors: Thura, Min, Ye, Zu, Al-Aidaroos, Abdul Qader, Xiong, Qiancheng, Ong, Jun Yi, Gupta, Abhishek, Li, Jie, Guo, Ke, Ang, Koon Hwee, Zeng, Qi
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thura and colleagues report that PRL3 promotes PGCCs, which are found to be enriched in relapsed tumours. The authors demonstrated that this relapse can be prevented using PRL3-zumab for use in adjuvant immunotherapy to target PRL3-expressing PGCCs, thus preventing metastasis and relapse.
ISSN:2399-3642
DOI:10.1038/s42003-021-02449-8